- Home
- SPAI vs PMVP Comparison
SPAI vs PMVP Comparison
Compare SPAI & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPAI | PMVP |
|---|---|---|
| Founded | 2021 | 2013 |
| Country | United States | United States |
| Employees | 15 | N/A |
| Industry | Industrial Specialties | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.5M | 66.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SPAI | PMVP |
|---|---|---|
| Price | $3.84 | $1.29 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 121.8K | ★ 352.1K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,060.58 | N/A |
| Revenue Next Year | $162.46 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.86 | $1.02 |
| 52 Week High | $9.16 | $1.88 |
Technical Indicators
Market Signals| Indicator | SPAI | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 38.77 | 53.15 |
| Support Level | $3.45 | $1.25 |
| Resistance Level | $4.74 | $1.50 |
| Average True Range (ATR) | 0.26 | 0.08 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 24.05 | 45.00 |
Price Performance
Historical ComparisonAbout SPAI Safe Pro Group Inc.
Safe Pro Group Inc operates to acquire security and protection products. The company operated in three reportable business segments, which consisted of the business of Safe-Pro USA, the business of Airborne Response, and the business of Safe Pro AI. The majority of revenue is from Safe-Pro USA.
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.